• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国医学遗传学与基因组学学院(ACMG)技术实验室标准 E6.7-6.12 部分:实体瘤获得性染色体异常的细胞遗传学研究。

Section E6.7-6.12 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory Standards: Cytogenomic studies of acquired chromosomal abnormalities in solid tumors.

机构信息

Department of Pathology, Boston Children's Hospital, Boston, MA; Harvard Medical School, Boston, MA.

The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH.

出版信息

Genet Med. 2024 Apr;26(4):101070. doi: 10.1016/j.gim.2024.101070. Epub 2024 Feb 20.

DOI:10.1016/j.gim.2024.101070
PMID:38376505
Abstract

Clinical cytogenomic studies of solid tumor samples are critical to the diagnosis, prognostication, and treatment selection for cancer patients. An overview of current cytogenomic techniques for solid tumor analysis is provided, including standards for sample preparation, clinical and technical considerations, and documentation of results. With the evolving technologies and their application in solid tumor analysis, these standards now include sequencing technology and optical genome mapping, in addition to the conventional cytogenomic methods, such as G-banded chromosome analysis, fluorescence in situ hybridization, and chromosomal microarray analysis. This updated Section E6.7-6.12 supersedes the previous Section E6.5-6.8 in Section E: Clinical Cytogenetics of the American College of Medical Genetics and Genomics Standards for Clinical Genetics Laboratories.

摘要

临床实体瘤样本细胞遗传学研究对于癌症患者的诊断、预后和治疗选择至关重要。本文概述了当前用于实体瘤分析的细胞遗传学技术,包括样本制备标准、临床和技术注意事项以及结果记录。随着技术的不断发展及其在实体瘤分析中的应用,这些标准现在包括测序技术和光学基因组图谱,除了传统的细胞遗传学方法,如 G 带染色体分析、荧光原位杂交和染色体微阵列分析。本更新的第 E6.7-6.12 节取代了美国医学遗传学与基因组学学院临床遗传学实验室标准(ACMG)的第 E6.5-6.8 节中的先前第 E6.5 节。

相似文献

1
Section E6.7-6.12 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory Standards: Cytogenomic studies of acquired chromosomal abnormalities in solid tumors.美国医学遗传学与基因组学学院(ACMG)技术实验室标准 E6.7-6.12 部分:实体瘤获得性染色体异常的细胞遗传学研究。
Genet Med. 2024 Apr;26(4):101070. doi: 10.1016/j.gim.2024.101070. Epub 2024 Feb 20.
2
Section E6.1-6.6 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory Standards: Cytogenomic studies of acquired chromosomal abnormalities in neoplastic blood, bone marrow, and lymph nodes.美国医学遗传学与基因组学学院(ACMG)技术实验室标准 E6.1-6.6 部分:肿瘤性血液、骨髓和淋巴结中获得性染色体异常的细胞遗传学研究。
Genet Med. 2024 Apr;26(4):101054. doi: 10.1016/j.gim.2023.101054. Epub 2024 Feb 13.
3
Section E6.5-6.8 of the ACMG technical standards and guidelines: chromosome studies of lymph node and solid tumor-acquired chromosomal abnormalities.美国医学遗传学与基因组学学会(ACMG)技术标准与指南的E6.5 - 6.8部分:淋巴结及实体瘤获得性染色体异常的染色体研究
Genet Med. 2016 Jun;18(6):643-8. doi: 10.1038/gim.2016.51. Epub 2016 Apr 28.
4
Section E6.1-6.4 of the ACMG technical standards and guidelines: chromosome studies of neoplastic blood and bone marrow-acquired chromosomal abnormalities.美国医学遗传学与基因组学学会(ACMG)技术标准和指南的E6.1 - 6.4部分:肿瘤性血液和骨髓的染色体研究——获得性染色体异常
Genet Med. 2016 Jun;18(6):635-42. doi: 10.1038/gim.2016.50. Epub 2016 Apr 28.
5
Chromosomal microarray analysis, including constitutional and neoplastic disease applications, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG).染色体微阵列分析,包括先天和肿瘤疾病应用,2021 年修订版:美国医学遗传学与基因组学学会(ACMG)的技术标准。
Genet Med. 2021 Oct;23(10):1818-1829. doi: 10.1038/s41436-021-01214-w. Epub 2021 Jun 15.
6
Section E9 of the American College of Medical Genetics technical standards and guidelines: fluorescence in situ hybridization.美国医学遗传学学院技术标准与指南 E9 部分:荧光原位杂交
Genet Med. 2011 Jul;13(7):667-75. doi: 10.1097/GIM.0b013e3182227295.
7
Section E6.5 of the ACMG technical standards and guidelines: chromosome studies for solid tumor abnormalities.ACMG 技术标准和指南 E6.5 部分:实体瘤异常的染色体研究。
Genet Med. 2009 Dec;11(12):890-7. doi: 10.1097/GIM.0b013e3181bb7808.
8
Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC).技术实验室标准用于解释和报告获得的拷贝数异常和肿瘤疾病中的杂合性丢失:美国医学遗传学与基因组学学会(ACMG)和癌症基因组学联盟(CGC)的联合共识建议。
Genet Med. 2019 Sep;21(9):1903-1916. doi: 10.1038/s41436-019-0545-7. Epub 2019 May 29.
9
American College of Medical Genetics and Genomics technical standards and guidelines: microarray analysis for chromosome abnormalities in neoplastic disorders.美国医学遗传学与基因组学学院技术标准与指南:肿瘤疾病相关染色体异常的微阵列分析
Genet Med. 2013 Jun;15(6):484-94. doi: 10.1038/gim.2013.49. Epub 2013 Apr 25.
10
Conventional Cytogenetic Analysis of Hematologic Neoplasms: A 20-Year Review of Proficiency Test Results From the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee.血液系统肿瘤的常规细胞遗传学分析:美国病理学家学院/美国医学遗传学与基因组学学院细胞遗传学委员会 20 年的能力验证结果回顾。
Arch Pathol Lab Med. 2021 Feb 1;145(2):176-190. doi: 10.5858/arpa.2020-0089-CP.

引用本文的文献

1
Detecting likely germline variants during tumor-based molecular profiling.在基于肿瘤的分子谱分析过程中检测可能的种系变异。
J Clin Invest. 2025 Aug 1;135(15). doi: 10.1172/JCI190264.
2
FASTKD1 as a diagnostic and prognostic biomarker for STAD: Insights into m6A modification and immune infiltration.FASTKD1作为胃癌的诊断和预后生物标志物:对m6A修饰和免疫浸润的见解
Exp Ther Med. 2024 May 31;28(2):305. doi: 10.3892/etm.2024.12594. eCollection 2024 Aug.